U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07301333) titled 'A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects' on Dec. 10.
Brief Summary: This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Pain
Intervention:
DRUG: HRS-6257
HRS-6257
DRUG: placebo
placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....